Page 83 | Certara

Publication

Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator

The article "Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system…

CertaraAugust 26, 2024

Publication

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)

The article “Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL)…

CertaraAugust 26, 2024

Press Coverage

The Uncertain Path Forward for Psychedelic Medicine

Certara's Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this…

CertaraAugust 26, 2024

Blog

Streamline your clinical trials with automated metadata management

When it comes to efficient clinical study build, content is king. Most importantly: metadata content.…

CertaraAugust 26, 2024

Blog

Regulatory requirements for annotated CRFs made easy

aCRFs are a key submission deliverable for any clinical trial. In this blog, we break…

CertaraAugust 26, 2024

Blog

Resmetirom: A pioneering NASH clinical program

Nonalcoholic fatty liver disease (NAFLD) is a condition wherein the liver stores excess fat. Nonalcoholic…

CertaraAugust 23, 2024

Press Coverage

Overcoming CMC Challenges in Cell and Gene Therapy: Part I

In this Manufacturing Chemist article, Certara's Drs. Hien Anh Bruno and Deven Shah discuss the…

CertaraAugust 23, 2024

Press Release

Certara to Participate in Upcoming Investor Conferences

RADNOR, Pa. — August 21, 2024 -- Certara, Inc. (Nasdaq: CERT), a global leader in…

CertaraAugust 21, 2024

Blog

Quantitative Systems Pharmacology (QSP) Modeling for Immunotherapy-induced Cytokine Release Syndrome

Cytokine Release Syndrome Cytokine release syndrome (CRS) is an inflammatory immune reaction that clinically manifests…

CertaraAugust 20, 2024

On-Demand Webinar

Navigating New Terrain: Joint Advice on FDA/EMA Compliance – Aligning with Evolving EU Regulations

Presentation Materials

CertaraAugust 20, 2024

Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)

The Uncertain Path Forward for Psychedelic Medicine

Streamline your clinical trials with automated metadata management

Regulatory requirements for annotated CRFs made easy

Resmetirom: A pioneering NASH clinical program

Overcoming CMC Challenges in Cell and Gene Therapy: Part I

Certara to Participate in Upcoming Investor Conferences

Quantitative Systems Pharmacology (QSP) Modeling for Immunotherapy-induced Cytokine Release Syndrome

Navigating New Terrain: Joint Advice on FDA/EMA Compliance – Aligning with Evolving EU Regulations

Newsletter sign up

Quick links

Solutions

Contact